Madrigal Pharmaceuticals Announces Publication in The Lancet of Positive Phase 2 Results for Resmetirom (MGL-3196) for the Treatment of Non-alcoholic Steatohepatitis (NASH)

Paul Theisen
Patient Acquisition

Pat Purcell
Meeting Engagement

Joey Cohen
Medication Adherence

Brenda Snow
Authentic Patient Voice

Matthew Durham
Omnidynamic Marketing

Daniel Sontupe
Market Access

Liz Kane
Impactful Strategy

Bud Bilanich
Success Coach

Frank Burrell
Scientific Storytelling

Stacey Gandler
Brand Nourishment

Suma Ramadas, PhD
Medical Affairs

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability

Amy Giles
Increasing Engagement